Filtered By:
Source: Molecular Cancer Therapeutics
Cancer: Liposarcoma

This page shows you your search results in order of date.

Order by Relevance | Date

Total 1 results found since Jan 2013.

CDK4/6 Inhibitor Reduces Human Liposarcoma Growth
In this study, we explored the role of CDK4 and the effects of NVP-LEE011 (LEE011), a novel selective inhibitor of CDK4/CDK6, on a panel of human liposarcoma cell lines and primary tumor xenografts. We found that both CDK4 knockdown by siRNA and inhibition by LEE011 diminished retinoblastoma (RB) phosphorylation and dramatically decreased liposarcoma cell growth. Cell-cycle analysis demonstrated arrest at G0–G1. siRNA-mediated knockdown of RB rescued the inhibitory effects of LEE011, demonstrating that LEE011 decreased proliferation through RB. Oral administration of LEE011 to mice bearing human liposarcoma xenograft...
Source: Molecular Cancer Therapeutics - September 2, 2014 Category: Cancer & Oncology Authors: Zhang, Y.-X., Sicinska, E., Czaplinski, J. T., Remillard, S. P., Moss, S., Wang, Y., Brain, C., Loo, A., Snyder, E. L., Demetri, G. D., Kim, S., Kung, A. L., Wagner, A. J. Tags: Small Molecule Therapeutics Source Type: research